Chordia Therapeutics Publishes Phase 1 Results of CLK Inhibitor Rogocekib for R/R AML/HR-MDS in Blood Advances (Follow-up announcement)
  • Jan 27, 2026
サブ-ナビゲーション
  • Company
    • CEO Message
    • Mission・2030 Vision
    • Leadership
    • Directors
    • Business Model
    • Brand Origin
    • Company Profile
  • Science/Pipleline
    • Focused Area
    • Pipeline Overview
    • CLK Inhibitor CTX-712
    • MALT1 Inhibitor CTX-177
    • CDK12 Inhibitor CTX-439
    • GCN2 Inhibitor CRD-1968099
  • News
  • Investor Relations
    • Management Policies
    • Financial Information
    • IR Library
    • Stock Information
    • IR Calender
    • 現在位置:IR News
    • IR FAQ
    • Disclaimer
  • Career
  • Contact
    • Contact
  • Privacy Policy
  • Term of use
  • Sitemap

Chordia Therapeutics Publishes Phase 1 Results of CLK Inhibitor Rogocekib for R/R AML/HR-MDS in Blood Advances (Follow-up announcement)

  • Jan 27, 2026

VIEW IR NEWS

ページの先頭へ
ページの先頭へ
  • footer-content
  • menu
  • gnavi-box